CRC Clinical Trial
Official title:
Evaluation of the Performance of the Motus Cleansing System
The study is multi-center study ,planned as a single arm, open trial, aimed at evaluating the performance and safety of a colon cleansing device during a colonoscopy procedure in a poorly prepared colons.
Total of 47 subjects are planned to be enrolled at 3 clinical sites (1 in Germany and 2 in
the Netherlands).
Subjects who meet the eligibility criteria will be screened for study participation at a
baseline visit(visit 1). Subject who is eligible to the study will required to follow a
specific reduced preparation instruction starting 2 days prior to the colonoscopy with the
Motus Cleansing System (MCS) procedure.
Following the procedure a telephone follow-up will be conducted at 48 hours (± 24 hours) and
14 days (± 3 days) post MCS procedure to assess patient well-being and capture any Adverse
Events (AE).
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05002270 -
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04981119 -
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
|
||
| Active, not recruiting |
NCT01308086 -
Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04585035 -
Study to Evaluate D-1553 in Subjects With Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03665285 -
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03336658 -
Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
|
||
| Terminated |
NCT03875313 -
Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05382377 -
NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors
|
Early Phase 1 | |
| Active, not recruiting |
NCT05314309 -
Prospective Clinical Validation of a Novel Multitarget FIT in CRC Screening
|
||
| Recruiting |
NCT06259552 -
A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors
|
Phase 1 | |
| Completed |
NCT05976282 -
Addressing Colorectal Cancer in South Florida Firefighters
|
N/A | |
| Recruiting |
NCT01593098 -
A Prospective Study Into the Risk of Colorectal Neoplasms in Individuals With a Family History of Advanced Adenomas (Sibling AN Study)
|
||
| Recruiting |
NCT03597581 -
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in 2nd Line RAS Mutant Advanced Colorectal Cancer
|
Phase 1 | |
| Terminated |
NCT05368688 -
Microbiome in Colorectal Cancer Onset and Progression
|
||
| Completed |
NCT03965845 -
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT03601598 -
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05009329 -
FIH Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation in China
|
Phase 1/Phase 2 | |
| Completed |
NCT02161549 -
Evaluation of the Motus Gl CleanUp System During Screening Colonoscopy
|
N/A | |
| Active, not recruiting |
NCT04868773 -
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
|
Phase 1 |